Mineralys Therapeutics (MLYS) Competitors

$27.38 +0.11 (+0.40%)

Closing price 04:00 PM Eastern

Extended Trading

$27.05 -0.33 (-1.21%)

As of 07:27 PM Eastern

MLYS vs. CYTK, KRYS, PRAX, IBRX, and NUVL

Should you buy Mineralys Therapeutics stock or one of its competitors? MarketBeat compares Mineralys Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mineralys Therapeutics include Cytokinetics (CYTK), Krystal Biotech (KRYS), Praxis Precision Medicines (PRAX), ImmunityBio (IBRX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.

How does Mineralys Therapeutics compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

Mineralys Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

In the previous week, Mineralys Therapeutics had 1 more articles in the media than Cytokinetics. MarketBeat recorded 23 mentions for Mineralys Therapeutics and 22 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.35 beat Mineralys Therapeutics' score of -0.01 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	4 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mineralys Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mineralys Therapeutics has lower revenue, but higher earnings than Cytokinetics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	107.20	-$784.96M	-$6.84	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

84.5% of Mineralys Therapeutics shares are held by institutional investors. 2.6% of Cytokinetics shares are held by insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cytokinetics currently has a consensus target price of $98.55, suggesting a potential upside of 29.93%. Mineralys Therapeutics has a consensus target price of $49.33, suggesting a potential upside of 80.18%. Given Mineralys Therapeutics' higher possible upside, analysts clearly believe Mineralys Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.82
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Cytokinetics has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

Summary

Mineralys Therapeutics beats Cytokinetics on 9 of the 15 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Krystal Biotech currently has a consensus target price of $324.11, suggesting a potential upside of 5.82%. Mineralys Therapeutics has a consensus target price of $49.33, suggesting a potential upside of 80.18%. Given Mineralys Therapeutics' higher probable upside, analysts plainly believe Mineralys Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Mineralys Therapeutics had 14 more articles in the media than Krystal Biotech. MarketBeat recorded 23 mentions for Mineralys Therapeutics and 9 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.86 beat Mineralys Therapeutics' score of -0.01 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mineralys Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Krystal Biotech has a net margin of 53.92% compared to Mineralys Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

Krystal Biotech has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	23.20	$204.83M	$7.48	40.95
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

Krystal Biotech has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market.

Summary

Krystal Biotech beats Mineralys Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Praxis Precision Medicines?

Mineralys Therapeutics (NASDAQ:MLYS) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

84.5% of Mineralys Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 18.9% of Mineralys Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Praxis Precision Medicines had 5 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 28 mentions for Praxis Precision Medicines and 23 mentions for Mineralys Therapeutics. Praxis Precision Medicines' average media sentiment score of 0.19 beat Mineralys Therapeutics' score of -0.01 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Praxis Precision Medicines	4 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Mineralys Therapeutics has higher earnings, but lower revenue than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
Praxis Precision Medicines	$8.55M	1,117.09	-$303.27M	-$13.37	N/A

Mineralys Therapeutics presently has a consensus price target of $49.33, indicating a potential upside of 80.18%. Praxis Precision Medicines has a consensus price target of $592.67, indicating a potential upside of 73.00%. Given Mineralys Therapeutics' higher possible upside, analysts plainly believe Mineralys Therapeutics is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95

Mineralys Therapeutics' return on equity of -27.92% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Mineralys Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.76, meaning that its share price is 176% more volatile than the broader market.

Summary

Mineralys Therapeutics and Praxis Precision Medicines tied by winning 7 of the 14 factors compared between the two stocks.

How does Mineralys Therapeutics compare to ImmunityBio?

Mineralys Therapeutics (NASDAQ:MLYS) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Mineralys Therapeutics has higher earnings, but lower revenue than ImmunityBio. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
ImmunityBio	$113.29M	73.68	-$351.40M	-$0.85	N/A

In the previous week, ImmunityBio had 28 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 51 mentions for ImmunityBio and 23 mentions for Mineralys Therapeutics. ImmunityBio's average media sentiment score of 0.21 beat Mineralys Therapeutics' score of -0.01 indicating that ImmunityBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImmunityBio	6 Very Positive mention(s)	1 Positive mention(s)	34 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Mineralys Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
ImmunityBio	-606.15%	N/A	-59.53%

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 69.5% of ImmunityBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Mineralys Therapeutics currently has a consensus price target of $49.33, indicating a potential upside of 80.18%. ImmunityBio has a consensus price target of $14.20, indicating a potential upside of 78.17%. Given Mineralys Therapeutics' higher possible upside, equities analysts plainly believe Mineralys Therapeutics is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Mineralys Therapeutics has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market.

Summary

ImmunityBio beats Mineralys Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Nuvalent?

Mineralys Therapeutics (NASDAQ:MLYS) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Mineralys Therapeutics had 8 more articles in the media than Nuvalent. MarketBeat recorded 23 mentions for Mineralys Therapeutics and 15 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.16 beat Mineralys Therapeutics' score of -0.01 indicating that Nuvalent is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvalent	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

84.5% of Mineralys Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 18.9% of Mineralys Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Nuvalent shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Mineralys Therapeutics' return on equity of -27.92% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
Nuvalent	N/A	-40.11%	-35.43%

Nuvalent is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Mineralys Therapeutics currently has a consensus price target of $49.33, indicating a potential upside of 80.18%. Nuvalent has a consensus price target of $137.25, indicating a potential upside of 34.16%. Given Mineralys Therapeutics' higher probable upside, research analysts clearly believe Mineralys Therapeutics is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.88

Mineralys Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Summary

Mineralys Therapeutics beats Nuvalent on 7 of the 12 factors compared between the two stocks.

Get Mineralys Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MLYS vs. The Competition

Export

Metric	Mineralys Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.25B	$3.32B	$6.23B	$12.27B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	N/A	18.21	20.16	25.23
Price / Sales	N/A	283.20	542.01	73.12
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	3.54	6.72	9.81	6.90
Net Income	-$154.65M	$24.16M	$3.56B	$333.88M
7 Day Performance	-7.31%	3.88%	0.27%	0.01%
1 Month Performance	-9.99%	-3.02%	-0.98%	1.75%
1 Year Performance	78.26%	68.84%	36.22%	32.67%

Mineralys Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MLYS Mineralys Therapeutics	3.6042 of 5 stars	$27.38 +0.4%	$49.33 +80.2%	+80.5%	$2.25B	N/A	N/A	28	Insider Trade
CYTK Cytokinetics	2.8006 of 5 stars	$74.07 -0.7%	$98.55 +33.0%	+162.1%	$9.21B	$88.04M	N/A	250	Analyst Forecast Insider Trade Options Volume Analyst Revision
KRYS Krystal Biotech	3.0819 of 5 stars	$310.19 -0.9%	$324.11 +4.5%	+140.7%	$9.14B	$389.13M	41.44	210
PRAX Praxis Precision Medicines	3.336 of 5 stars	$323.82 -2.4%	$591.83 +82.8%	+831.3%	$9.03B	$8.55M	N/A	110	Analyst Forecast Analyst Revision Gap Down
IBRX ImmunityBio	3.2247 of 5 stars	$7.92 -2.4%	$14.20 +79.3%	+227.3%	$8.29B	$140.98M	N/A	590	Trending News Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MLYS) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mineralys Therapeutics (MLYS) Competitors

MLYS vs. CYTK, KRYS, PRAX, IBRX, and NUVL

How does Mineralys Therapeutics compare to Cytokinetics?

Summary

How does Mineralys Therapeutics compare to Krystal Biotech?

Summary

How does Mineralys Therapeutics compare to Praxis Precision Medicines?

Summary

How does Mineralys Therapeutics compare to ImmunityBio?

Summary

How does Mineralys Therapeutics compare to Nuvalent?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLYS vs. The Competition

Mineralys Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mineralys Therapeutics (MLYS) Competitors

MLYS vs. CYTK, KRYS, PRAX, IBRX, and NUVL

How does Mineralys Therapeutics compare to Cytokinetics?

Is CYTK or MLYS more profitable?

Does the media favor CYTK or MLYS?

Which has better earnings and valuation, CYTK or MLYS?

Do insiders and institutionals have more ownership in CYTK or MLYS?

Do analysts recommend CYTK or MLYS?

Which has more volatility and risk, CYTK or MLYS?

Summary

How does Mineralys Therapeutics compare to Krystal Biotech?

Do analysts prefer KRYS or MLYS?

Do insiders and institutionals believe in KRYS or MLYS?

Does the media favor KRYS or MLYS?

Is KRYS or MLYS more profitable?

Which has stronger earnings & valuation, KRYS or MLYS?

Which has more risk and volatility, KRYS or MLYS?

Summary

How does Mineralys Therapeutics compare to Praxis Precision Medicines?

Do insiders & institutionals believe in MLYS or PRAX?

Does the media prefer MLYS or PRAX?

Which has higher valuation and earnings, MLYS or PRAX?

Do analysts prefer MLYS or PRAX?

Is MLYS or PRAX more profitable?

Which has more volatility & risk, MLYS or PRAX?

Summary

How does Mineralys Therapeutics compare to ImmunityBio?

Which has better earnings & valuation, MLYS or IBRX?

Does the media refer more to MLYS or IBRX?

Is MLYS or IBRX more profitable?

Do institutionals and insiders have more ownership in MLYS or IBRX?

Do analysts recommend MLYS or IBRX?

Which has more volatility and risk, MLYS or IBRX?

Summary

How does Mineralys Therapeutics compare to Nuvalent?

Does the media refer more to MLYS or NUVL?

Do insiders & institutionals have more ownership in MLYS or NUVL?

Is MLYS or NUVL more profitable?

Which has preferable earnings and valuation, MLYS or NUVL?

Do analysts recommend MLYS or NUVL?

Which has more risk and volatility, MLYS or NUVL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLYS vs. The Competition

Mineralys Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools